GPCR Therapeutics launches multiple myeloma trial
GPCR Therapeutics, Inc., a drug discovery company targeting G Protein Coupled Receptors (GPCR) pairs, has…
GPCR Therapeutics, Inc., a drug discovery company targeting G Protein Coupled Receptors (GPCR) pairs, has…
Sosei Heptares has entered translational medicine and R&D agreements with the MRC Weatherall Institute of…
PrecisionLife, developers of precision medicine for chronic diseases, will be supporting biopharmaceutical group, Sosei Heptares,…
The UK firm OMass Therapeutics has unveiled a €90M (£75.5M) Series B financing to bankroll…
Confo Therapeutics has raised €30M in a Series A round that will take its unique…
Richard Henderson, awarded the Nobel Prize in Chemistry 2017, founded Heptares Therapeutics to apply his Nobel-winning technology…
He is a young entrepreneur with a fast growing company. His software for the automation…
Confo and Lundbeck have joined forces to push through drug discovery against a tough-to-target protein…
Allergan's partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat…
Heptares is expanding into a range of indications with its GPCR platform. I caught up…
UPDATE (19/05/2017): MorphoSys has announced the completion of the Phase I study with MOR107, which…
The UK biotech attacking notoriously evasive GPCRs has discovered a small molecule that could be…